中国抗体制药有限公司（中国抗体-B，股票代码：03681）于2026年8月6日披露了截至2026年7月31日的证券变动月报表。公告显示，本月公司注册股本未发生变动，仍保持在1,386,638,336股，且未进行任何新增发行、购回或注销活动，股本维持不变。
根据月报信息，认股期权方面，公司于2022年10月26日通过并于2024年6月14日修订的购股权计划，上月底结存股份期权数量为69,491,262份，本月内新增授出18,026,040份，期末合计增至87,517,302份。同时，本月未有因行使期权产生的新股发行或由库存转让的股份。截至本月底，该计划下仍可能发行或转让16,926,100股，若所有已授予期权悉数行使，预计合计可能发行或转让34,019,409股。
公司在报告中确认已遵守香港联交所《上市规则》和相关法律法规的要求。公告由执行董事、主席兼首席执行官梁瑞安签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.